The U.S. FDA has approved AstraZeneca PLC (AZN) and Daiichi Sankyo's (TYO: 4568) fam-trastuzumab deruxtecan (Enhertu) in combination with pertuzumab for first-line treatment of HER2-positive breast cancer. This decision follows the DESTINY-Breast09 trial, which demonstrated a median progression-free survival (PFS) of 40.7 months for the Enhertu regimen, significantly outperforming the standard THP regimen's 26.9 months. Pertuzumab is marketed by Roche (SWX: ROG).